How India Exports Pyrimethamine to the World

In the United States, pyrimethamine is approved for the treatment of toxoplasmosis and as a prophylactic agent against malaria. According to the FDA's Orange Book, multiple Abbreviated New Drug Applications (ANDAs) for pyrimethamine have been approved, indicating a competitive generic market. However, specific details regarding the number of approved ANDAs and recent approvals are not readily available in the provided data.

Regarding import alerts, as of February 19, 2026, the FDA issued Import Alert 66-41, which pertains to the detention without physical examination of unapproved new drugs promoted in the U.S. While this alert does not specifically mention pyrimethamine, it underscores the FDA's vigilance in monitoring drug imports. Additionally, Import Alert 66-66, updated on October 22, 2024, addresses active pharmaceutical ingredients (APIs) that appear to be misbranded under section 502(f)(1) due to labeling deficiencies. This alert could potentially impact pyrimethamine imports if labeling requirements are not met.

Given the presence of 70 active Indian exporters and 118 buyers, with a repeat buyer rate of 50.8%, the U.S. market for pyrimethamine appears robust. However, exporters must ensure compliance with FDA regulations to maintain market access.

In the European Union (EU) and the United Kingdom (UK), pyrimethamine is subject to stringent regulatory oversight. Marketing authorization is granted by the European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA), respectively. Manufacturers must comply with Good Manufacturing Practice (GMP) requirements as stipulated by EU directives and UK regulations. Specific actions or updates regarding pyrimethamine by the EMA or MHRA are not detailed in the provided data.

Pyrimethamine is listed in the 22nd edition of the WHO Model List of Essential Medicines (2021), highlighting its importance in treating malaria and toxoplasmosis. The WHO Prequalification Programme has prequalified pyrimethamine APIs from manufacturers such as Anuh Pharma Ltd. (prequalified on September 25, 2020) and Mangalam Drugs and Organics Ltd. (prequalified on December 16, 2019). (extranet.who.int) These prequalifications facilitate procurement by UN agencies and other organizations. Pyrimethamine formulations are included in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality across markets.

In India, pyrimethamine is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, specific ceiling prices for pyrimethamine are not detailed in the provided data. For exports, the Directorate General of Foreign Trade (DGFT) may require a No Objection Certificate (NOC) to ensure compliance with national and international regulations.

Pyrimethamine's primary patents have expired, leading to a competitive generic market. This is evidenced by the presence of multiple Indian exporters and a diverse range of international buyers.

In September 2025, the WHO Prequalification Unit added new dispersible tablet formulations combining amodiaquine and sulfadoxine/pyrimethamine, manufactured by Ajanta Pharma Limited, to its prequalified list. (extranet.who.int) This development enhances the availability of child-friendly antimalarial treatments.

In October 2024, the FDA updated Import Alert 66-66, focusing on APIs that appear to be misbranded due to labeling deficiencies. This underscores the importance of compliance with labeling requirements for exporters targeting the U.S. market.

In February 2026, the FDA issued Import Alert 66-41, concerning the detention without physical examination of unapproved new drugs promoted in the U.S. While not specific to pyrimethamine, this alert highlights the FDA's ongoing efforts to monitor drug imports.

In March 2026, the FDA issued Import Alert 16-120, detaining without physical examination fish and fishery products from foreign processors not in compliance with seafood HACCP regulations. Although unrelated to pyrimethamine, this reflects the FDA's stringent import controls across various sectors.

In March 2026, the FDA issued Import Alert 99-45, detaining without physical examination food products that are or contain an unsafe food additive. This alert emphasizes the FDA's commitment to ensuring the safety of imported food products.

These developments highlight the dynamic regulatory environment affecting pyrimethamine exports and underscore the necessity for exporters to stay informed and compliant with international standards.

Pyrimethamine's production is heavily reliant on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs), with a significant portion sourced from China. China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a dominant player in the API industry. This dependency exposes the supply chain to risks associated with geopolitical tensions, trade restrictions, and environmental regulations. For instance, in 2022, environmental inspections in China led to the temporary shutdown of major API facilities in Shandong province, causing delays in pyrimethamine precursor shipments and reducing finished product availability in malaria-endemic regions like Papua New Guinea by 40% during peak transmission seasons.

India's reliance on Chinese imports for APIs and KSMs is substantial, with approximately 70% of its APIs sourced from China. This overdependence poses significant risks to India's pharmaceutical supply chain and healthcare security, especially in the face of geopolitical tensions and global supply chain disruptions. To mitigate these risks, India has initiated the Production Linked Incentive (PLI) scheme to bolster domestic production of APIs and KSMs. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules like Penicillin G and Clavulanic Acid, aiming to reduce import dependence by half.

The export market for pyrimethamine from India is highly concentrated, with the top five exporters accounting for 83.2% of the total export value. S KANT HEALTHCARE LIMITED leads with a 58.2% share, followed by MACLEODS PHARMACEUTICALS LTD (8.6%), IPCA LABORATORIES LIMITED (8.4%), FOURRTS (INDIA) LABORATORIES PRIVATE LIMITED (4.1%), and MEDOPHARM (3.9%). This high concentration increases the risk of supply disruptions if any of these key suppliers face operational challenges.

To address such vulnerabilities, the Indian government launched the PLI scheme in February 2021, aiming to reduce import dependence on critical APIs and KSMs. By October 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules, marking a significant step towards self-reliance. However, the effectiveness of this initiative in diversifying the supplier base for pyrimethamine remains to be fully realized.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are susceptible to geopolitical tensions that can disrupt the transportation of pharmaceutical products. Additionally, U.S.-China trade tensions have led to increased scrutiny and potential tariffs on pharmaceutical imports, affecting the cost and availability of APIs and KSMs. Such disruptions can lead to shortages and increased prices for essential medications like pyrimethamine.

Regulatory bodies such as the FDA and EMA have issued shortage alerts for various medications due to supply chain disruptions. For example, in July 2024, the FDA reported shortages of certain antibiotics due to supply chain issues stemming from API sourcing challenges. These incidents underscore the importance of a resilient and diversified supply chain for critical pharmaceuticals.

• Diversify API and KSM Sources: Identify and qualify alternative suppliers from different geographic regions to reduce dependency on a single country.

• Enhance Domestic Production: Invest in local manufacturing capabilities for APIs and KSMs, leveraging government incentives like the PLI scheme to build a more self-reliant supply chain.

• Strengthen Supplier Relationships: Develop strategic partnerships with multiple suppliers to ensure a stable and reliable supply of raw materials.

• Monitor Geopolitical Developments: Establish a proactive monitoring system to assess and respond to geopolitical events that may impact supply chains.

• Implement Risk Management Frameworks: Develop comprehensive risk assessment and mitigation strategies to address potential supply chain disruptions.

RISK_LEVEL: HIGH